Круглосуточно
+7 (965) 177 17 74

бесплатно по России

цаталодж 670604

If a patient tests positive for SARS-CoV-2 and/or develops COVID-19, discontinuation of biologics should be considered until the patient clears the infection. JAK inhibitors (tofacitinib and others) selectively affect the intracellular JAK/STAT signaling system, which mediates the action of many cytokines involved in the pathogenesis of ulcerative colitis. Unlike genetically engineered biological drugs, inhibition

"На тот момент я считал, что лучше уж смерть, чем быть без конечностей. Был такой случай, что я получил гранату, хотел взорвать себя, сказал товарищам, чтобы отошли, но они сказали: "Нет, если у тебя есть желание, давай вместе с нами". И я ее спрятал. Товарищи меня спасли, тащили через ад. Я им много раз говорил, оставьте меня, где-то среди домов, вернитесь, если я буду жив. Но они сказали, что мы тебя не оставим и тянули. Возле нас разрывались снаряды, а они не испугались, вовремя меня дотянули. Я благодарен товарищам и не имею права их подвести. Должен жить дальше, чтобы они не зря рисковали своей жизнью", - говорит Михаил Юрчук.

5-ASA preparations have very weak immunosuppressive activity. There are no reports that these drugs are associated with an increased risk of infection, and studies evaluating the safety profile of 5-ASA do not show an increased risk of serious or opportunistic infections. Treatment with 5-ASA should be continued without concern for an increased risk of infection or severe COVID-19. If the patient is in contact with a patient with COVID-19 or develops COVID-19, treatment with 5-ASA should be continued.

Treatment with corticosteroids (especially prednisolone ≥20 mg/day or equivalent) is associated with an increased risk of infection. However, it is unclear whether corticosteroid therapy is associated with an increased risk of developing COVID-19 or its complications. Data on budesonide, a topical corticosteroid with low systemic bioavailability, show that these drugs are associated with significantly fewer side effects compared to systemic corticosteroids and their side effects are close to placebo. If possible, corticosteroids should be avoided and a rapid dose reduction considered, and a switch to budesonide is recommended. This must be taken into account, taking into account the risk of exacerbation of CKD. If a patient with COPD is in contact with a person with COVID-19 or develops COVID-19, it is recommended to gradually reduce the dose of corticosteroids, the use of budesonide is preferred, but taking into account the severity of COPD and the risk of exacerbation.

Быстрая запись на прием

Ваше имя:* Телефон:* Выберите специализацию:* Выберите врача:

Дополнительная информация: